Abstract:Drug development is a very time, capital, and labor-intensive process. It was anticipated that bringing a novel chemical entityto market would take over a billion dollars and around 14 years [1]. In addition, drug development is characterized by avery high attrition rate both in preclinical and clinical studies. It was reported that only 40% of drug candidates with the mostdrug-like properties could make their way into clinical trials, and only 10% of these can eventually reach FDA approval [2].After analyzing the data from seven UK‐based pharmaceutical companies from 1964 through 1985, Prentis et al. found that39% of failure was attributed to poor pharmacokinetic (PK) profiles in humans, 29% was attributed to a lack of clinical efficacy,21% was attributed to toxicity and adverse effects, and about 6% was attributed to commercial limitations [3]. When adrug candidate is identified with one of these issues (except the commercial limitations), normally, a new round of structureactivityor structure-property relationship (SAR/SPR) studies is carried out to generate a new chemical entity with improvedprofiles, and in most cases, such a process is time and labor-intensive. Alternatively, prodrug strategy can be leveraged to efficientlyaddress associated drug developability issues without making enormous derivatives. Prodrug strategy has been demonstratedto be very successful and fruitful in drug development, with around 20% of approved drugs from 2008 through 2020being clarified as prodrugs [4]. In recent years, prodrug strategy has also been leveraged to address the delivery issues associatedwith gasotransmitters, including NO, H2S, CO as well as SO2 [5-8]. In this thematic issue, six excellent reviews wereincluded, focusing on varied prodrug strategies in addressing different drug developability issues associated with anticancerdrugs, central nervous system (CNS) drugs, and gasotransmitters....

[Research of Oral Prodrugs: Opportunities and Challenges].

Modern Prodrug Design for Targeted Oral Drug Delivery

Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.

Advances in Oral Drug Delivery Systems: Challenges and Opportunities

Prodrug Strategies for Critical Drug Developability Issues: Part II

Research of Prodrugs in Pharmaceutics

Advances in Brain-targeting Prodrugs Based on “Lock-In” Chemical Delivery System

Research on the Pharmacokinetics of Prodrugs

Prodrug Rewards in Medicinal Chemistry: An Advance and Challenges Approach for Drug Designing

Is prodrug design an approach to increase water solubility?

Drug complexes: Perspective from Academic Research and Pharmaceutical Market

Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals

Prodrug Strategies in the CNS Drugs: Small Modification Makes Big Improvements

Review On Prodrug : An Advance Approach for The Drug Design to Enhance the Therapeutic Efficacy

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Oral Patch/Film for Drug Delivery-Current Status and Future Prospects

Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates

Advances in Oral Drug Delivery

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years

Oral Nano-Delivery Systems for Colon Targeting Therapy.

The expanding role of prodrugs in contemporary drug design and development